Objective It is to evaluate the safety and efficacy of Yin YiTM paclitaxel-eluting stent in the interventional therapy for non ST elevation acute coronary syndrome. Methods 97 patients with non ST elevation acute coronary syndrome were randomly divided into two groups : 47 cases in experimental group and 50 cases in control group. and they were implanted 60 Yin YiTM paclitaxel-eluting stents and 72 Partner stents respectively. MACE after 6 months and after 30 days, ISR after 6 months were in both groups followed up after operation. Results There was no cardiogenic death case and non-fetal myocardial infarction case during six months' following up in both group. 8 cases with stent restenosis in experimental group and 3 cases in control group were found by coronary arteriongraphy, and they were treated with stent balloon dilatation. All the operations were successful. Conclusion In 6 months after Yin YiTM paclitaxel-eluting stent implanting, coronary artery restenosis rate and MACE occurrence rate is similar to Partner stent. This conclusion still need to be further confirmed by large-scale , multicenter, randomized controlled trials.%目的 评价垠艺TM紫杉醇微孔载药支架在非ST段抬高急性冠脉综合征介入治疗中的安全性和有效性.方法 将97例非ST段抬高急性冠脉综合征患者随机分为实验组47例和对照组50例,分别置入垠艺TM紫杉醇药物涂层支架60枚和Partner支架72枚.随访术后6个月2组不良心脏事件(MACE)发生率,术后30d MACE及术后6个月再狭窄率.结果 2组随访6个月,均无心源性死亡、非致死性心肌梗死.实验组8例、对照组3例冠脉造影复查时发现支架内再狭窄,予行支架内球囊扩张术治疗,手术成功.结论 置入垠艺TM紫杉醇药物涂层支架术后6个月,冠脉再狭窄率和MACE发生率与置入Partner者相似,这一结论仍有待大规模、多中心的随机对照试验进一步证实.
展开▼
